This antibody detects PION at C-term. Multiple isoforms of PION are known to exist. PION antibody is predicted to not cross-react with other F-box protein family members.
Cross-Reactivity (Details)
Species reactivity (tested):Human, mouse, rat
Purification
Affinity chromatography purified via peptide column
Immunogen
19 amino acid peptide near the carboxy terminus of human PION
Accumulation of the amyloid-β peptide (Aβ) in the cerebral cortex is a critical event in the pathogenesis of Alzheimer s disease. The β-amyloid protein precursor (APP) is cleaved by one of two β-secretases (BACE and BACE2), producing a soluble derivative of the protein and a membrane anchored 99 -amino acid carboxy-terminal fragment (C99). The C99 fragment serves as substrate for γ?secretase to generate the 4 kDa amyloid-β peptide (Aβ), which is deposited in the Alzheimer's disease patients' brains. PION, or GSAP, selectively increases amyloid-beta production through a mechanism involving its interaction with both gamma-secretase and the APP C-terminal fragment, suggesting that PION may be a potential therapeutic target for the treatment of Alzheimer's disease.Synonyms: Gamma-secretase-activating protein, Protein pigeon homolog